Pharmaceutical Quality Management Software (QMS) Market by Process (Clinical Trial, Regulatory, Manufacturing, Commercialization), Application (eSOP, CAPA, Compliance), Size (Large, Small), End User (pharma, biotech, CRO), Region - Global Forecast to 2030

icon1
USD 1.41 BN
MARKET SIZE, 2030
icon2
CAGR 13.3%
(2025-2030)
icon3
240
REPORT PAGES
icon4
90
MARKET TABLES

OVERVIEW

pharmaceutical quality management software market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global pharmaceutical quality management software market is projected to reach USD 2.98 billion by 2030 from USD 1.59 billion in 2025, at a high CAGR of 13.3% during the forecast period. The pharmaceutical quality management software market is gaining significant traction, driven by the industry’s increasing focus on product safety, regulatory compliance, and operational efficiency.

KEY TAKEAWAYS

  • BY PROCESS
    The Pharmaceutical Quality Management Software market, by process, spans Clinical Trials, Regulatory Compliance, Manufacturing/Production, Quality Assurance/Quality Control, Distribution & Supply Chain, Commercialization, Marketing & Sales, Post-Market Surveillance, and Others. Growth in this segment is driven by the need to standardize and automate quality workflows across clinical, manufacturing, and post-market operations, ensuring end-to-end compliance and audit readiness.
  • BY APPLICATION
    By application, the market is segmented into Document Control & eSOP, CAPA (Corrective & Preventive Action) Management, Audit & Inspection Management, Training Management, Regulatory & Compliance Management, Supplier Quality Management, Risk Management, Change Control Management, and Others (Equipment Management, Non-Conformance Handling, etc.). Adoption is propelled by the increasing requirement for integrated platforms that manage CAPA, document control, and regulatory activities through a unified digital framework.
  • BY ENTERPRISE SIZE
    By enterprise size, the market is divided into Large Enterprises and Small & Medium Enterprises (SMEs). Demand across enterprise sizes is supported by the shift toward cloud-based, scalable QMS solutions that reduce validation complexity and enable remote compliance management.
  • BY END USER
    By end user, the market is categorized into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and Others. Expansion among end users is driven by the growing focus on regulatory transparency and quality consistency across pharma, biotech, CRO, and CDMO collaborations.
  • BY REGION
    The Pharmaceutical Quality Management Software market covers Europe, North America, Asia Pacific, Latin America, Middle East & Africa. Asia Pacific is emerging as the fastest-growing region, supported by rapid pharmaceutical manufacturing expansion, evolving regulatory frameworks, and accelerated digitalization of quality systems.
  • COMPETITIVE LANDSCAPE
    The major market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Veeva Systems Inc. (US), MasterControl Solutions, Inc. (US), Honeywell International Inc. (US), IQVIA (US), Qualio, Inc. (US), and Hexagon AB (Sweden) entered into several agreements and partnerships to cater to the growing demand for pharmaceutical quality management infrastructure.

The Pharmaceutical Quality Management Software market is driven by rising regulatory compliance pressures, digital transformation of manufacturing, increasing focus on risk and quality management, cloud-based deployment adoption, and growing demand for data-driven, automated systems ensuring traceability, audit readiness, and operational efficiency.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on the Pharmaceutical Quality Management Software market arises from evolving customer trends and operational disruptions. End users such as pharma, biotech, CROs, and CDMOs are key clients of the pharmaceutical quality management technology providers. Shifts toward digitalization, AI-driven risk management, and regulatory tightening are reshaping quality processes across the pharma value chain. These disruptions influence the revenue performance of pharma manufacturers and service partners, which in turn directly affects the demand, innovation pace, and revenue streams of pharmaceutical quality management technology vendors.

pharmaceutical quality management software market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Stringent regulatory compliance pressures are pushing pharma companies to adopt QMS solutions
  • Globalization of pharmaceutical operations is driving the need for digitalization and automation of QMS systems
RESTRAINTS
Impact
Level
  • Strict data protection laws (GDPR, HIPAA) raise cybersecurity costs and slow software adoption
  • Reluctance to adapt to new software solutions
OPPORTUNITIES
Impact
Level
  • Increasing demand for specialized cloud-based software solutions in pharma manufacturing
  • Expansion across emerging regions, fuelled by rising pharmaceutical manufacturing activities and evolving regulatory frameworks
CHALLENGES
Impact
Level
  • Variability in regulatory standards across regions
  • High initial costs of pharma QMS solutions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Stringent regulatory compliance pressures are pushing pharma companies to adopt QMS solutions

Pharmaceutical manufacturers face escalating scrutiny from regulatory bodies like the FDA, EMA, and WHO, particularly following high-profile drug recalls and contamination incidents. The FDA's modernized quality metrics program and the EU's Annex 1 revisions mandate comprehensive electronic batch record systems, real-time deviation tracking, and audit trail capabilities that paper-based systems cannot deliver. The quality management software automates 21 CFR Part 11 compliance, streamlines CAPA management, and maintains perpetual GMP readiness. With regulatory inspections now demanding data integrity evidence within hours rather than days, companies face potential market withdrawals and revenue losses exceeding millions per incident, making QMS adoption a financial imperative rather than an optional investment.

Restraint: Strict data protection laws (GDPR, HIPAA) raise cybersecurity costs and slow software adoption

GDPR's penalties and HIPAA's criminal liability provisions force pharma quality management software vendors to implement military-grade encryption, multi-factor authentication, and continuous penetration testing infrastructure. Patient data tokenization, anonymization engines, and geographic data residency requirements necessitate duplicate server architectures across jurisdictions, inflating operational costs by 40-60%. Small and mid-sized pharmaceutical companies, particularly in emerging markets, struggle with the high annual cybersecurity budget required for compliant cloud QMS platforms. Additionally, mandatory breach notification protocols and cyber insurance premiums create ongoing financial burdens, while lengthy security audits, often 6-9 months, delay deployment timelines and reduce ROI appeal.

Opportunity: Increasing demand for specialized cloud-based software solutions in pharma manufacturing

The shift toward biologics, cell therapies, and personalized medicines requires QMS platforms with advanced capabilities: cold chain monitoring for temperature-sensitive products, genealogy tracking for patient-specific treatments, and real-time batch release protocols. Contract Development and Manufacturing Organizations (CDMOs) managing 50+ client specifications simultaneously need multi-tenant cloud architectures with client-specific validation protocols. AI-powered predictive quality analytics can reduce out-of-specification events by 35%, while IoT integration with manufacturing equipment enables automated process deviation alerts. The CDMO market growth and outsourcing trends create demand for scalable, validation-ready SaaS QMS solutions offering pay-per-batch pricing models tailored to flexible manufacturing environments.

Challenge: Variability in regulatory standards across regions

Pharmaceutical Quality management software must simultaneously satisfy FDA's risk-based approach, EMA's centralized authorization procedures, China's NMPA evolving standards, and India's Schedule M requirements, each with conflicting documentation formats and validation expectations. A CAPA workflow approved for US operations may violate EU's GMP Annex 11 electronic signature requirements, forcing expensive custom development. Japanese PMDA's preference for Japanese-language interfaces and Brazil's ANVISA requiring local server hosting creates fragmentation that prevents economies of scale. Multinational manufacturers spend million annually maintaining parallel QMS configurations, delaying market entry and reducing competitive agility in fast-moving markets.

pharmaceutical quality management software market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Cloud-based QMS unifying quality, CAPA, and supplier oversight across global pharma operations. Faster audit readiness, enterprise-wide visibility, and stronger regulatory confidence.
Integrated QMS and batch record automation replacing paper-heavy QA workflows. Shortens release cycles, reduces manual errors, and ensures end-to-end compliance.
Enterprise QMS connecting audits, complaints, and supplier quality across multi-site networks. Standardizes global quality operations and accelerates product approvals.
Provides an integrated digital QMS through the BIOVIA platform for managing compliance, CAPA, and laboratory quality processes in pharma manufacturing. Enhances regulatory compliance, data integrity, and product quality through unified digital workflows.
Delivers cloud-based QMS and manufacturing execution solutions enabling pharma companies Improves process efficiency, real-time visibility, and reduces deviation and batch-release cycle times

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The pharmaceutical quality management software (QMS) ecosystem consists of key players (Honeywell, MasterControl, Veeva, Dassault Systèmes) providing integrated cloud-based QMS platforms; other players (SimplerQMS, KIVO, Qualityze) offering specialized niche solutions; cloud service providers (AWS, Microsoft Azure, IBM Cloud) delivering secure, GxP-validated infrastructure; and end users (Sanofi, Pfizer, Lilly, Novo Nordisk) implementing solutions for regulatory compliance and operational efficiency

pharmaceutical quality management software market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

pharmaceutical quality management software market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Pharmaceutical Quality Management Software Market, By Process

In 2024, the Manufacturing/ production segment held the largest share of the pharmaceutical quality management software market, as companies prioritized digitalizing GMP compliance, batch release, and deviation management. This phase handles the highest regulatory risk and operational complexity, driving investment in integrated QMS–MES–LIMS platforms. Vendors gain strong traction by enabling real-time quality control, automated CAPA, and electronic batch records, delivering measurable ROI through reduced downtime, faster product release, and improved audit readiness across global manufacturing operations.

Pharmaceutical Quality Management Software Market, By Application

In 2024, CAPA management held the largest share of the pharmaceutical quality management software market by application, as it serves as the backbone of regulatory compliance and continuous improvement. Pharmaceutical manufacturers prioritize CAPA solutions to systematically investigate deviations, implement corrective measures, and prevent recurrence, which is key for FDA and EMA audit readiness. Advanced CAPA modules integrate with document control, risk management, and change management systems, enabling end-to-end traceability, faster closure rates, and data-driven decision-making that directly impacts product quality and regulatory outcomes.

Pharmaceutical Quality Management Software Market, By Enterprise Size

In 2024, large enterprises held the largest share of the pharmaceutical quality management software market by enterprise size due to their extensive manufacturing networks, complex quality processes, and stringent global compliance requirements. These organizations invest heavily in enterprise-grade QMS platforms that integrate with ERP, MES, and LIMS systems to standardize quality operations across multiple sites. Their focus on audit readiness, data integrity, and digital transformation drives higher software adoption, customization, and long-term vendor partnerships compared to mid-sized or small pharmaceutical companies.

Pharmaceutical Quality Management Software Market, By End user

In 2024, Pharmaceutical companies dominated the end-user segment of the pharmaceutical quality management software market as they rely on advanced QMS platforms to manage quality across high-volume, multi-site manufacturing and contract ecosystems. Rising regulatory enforcement around data integrity, digital batch release, and serialization compliance has accelerated QMS deployment across formulation, biologics, and sterile manufacturing lines. Firms are integrating QMS with MES and LIMS to enable closed-loop deviation-to-CAPA control, electronic validation, and predictive quality analytics directly linking quality outcomes to supply continuity and release velocity.

REGION

Asia Pacific to be fastest-growing region in global Pharmaceutical Quality Management Software market during forecast period

Asia-Pacific emerges as the fastest-growing pharmaceutical quality management software market, driven by China and India's expanding generic manufacturing sectors, increasing regulatory convergence with ICH guidelines, and government mandates for digital quality compliance. Rapid CDMO growth in Singapore, South Korea, and Malaysia attracts multinational partnerships requiring validated QMS infrastructure. Rising biologics production, particularly biosimilars, necessitates sophisticated electronic batch records and traceability systems. Cost-effective cloud adoption, supportive digital health policies, and growing pharmaceutical exports to regulated markets accelerate regional QMS investment, with compound annual growth rates exceeding global averages.

pharmaceutical quality management software market Region

pharmaceutical quality management software market: COMPANY EVALUATION MATRIX

In the pharmaceutical quality management software market matrix, Veeva Systems (Star) leads with a dominant market position and a robust cloud-based quality portfolio, driven by its Veeva Vault QMS platform and deep integration across regulatory, clinical, and manufacturing workflows. The company’s strong foothold among global pharmaceutical and biotech firms is reinforced by its GxP-compliant architecture, seamless data connectivity, and proven scalability across enterprise deployments. ComplianceQuest (Emerging Leader) is rapidly gaining traction through its Salesforce-native QMS platform, offering agile, modular solutions for mid- to large-scale pharma clients focused on digital transformation, real-time compliance monitoring, and AI-enabled deviation and CAPA management.

pharmaceutical quality management software market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 1.41 BN
Market Forecast in 2030 (value) USD 2.98 BN
Growth Rate CAGR of 13.31% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends.
Segments Covered
  • By Process:
    • Clinical Trials
    • Regulatory Compliance
    • Manufacturing/Production
    • Quality Assurance/Quality Control
    • Distribution & Supply Chain
    • Commercialization
    • Marketing & Sales
    • Post-Market Surveillance
    • Others.
  • By Application:
    • Document Control & eSOP
    • CAPA (Corrective & Preventive Action) Management
    • Audit & Inspection Management
    • Training Management
    • Regulatory & Compliance Management
    • Supplier Quality Management
    • Risk Management
    • Change Control Management
    • Others.
  • By Enterprise Size: Large Enterprises and Small & Medium Enterprises (SMEs).
  • By End User:
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations (CROs)
    • Contract Development and Manufacturing Organizations (CDMOs)
    • Others.
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: pharmaceutical quality management software market REPORT CONTENT GUIDE

pharmaceutical quality management software market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Local Competitive Landscape Profiles of key QMS vendors (e.g., MasterControl, Veeva, Honeywell, Dassault Systèmes) covering segmental presence, pharma client base, pricing tiers, regulatory focus, and cloud/AI integration roadmap. Enables competitive benchmarking, identifies functional and compliance gaps, and supports vendor selection, partnership evaluation, and market positioning strategies.
Regional Market Entry Strategy In-depth assessment of regional compliance mandates (FDA, EMA, CDSCO, PMDA), digital readiness, pharma manufacturing clusters, and localization needs for validation, hosting, and audit support. Reduces entry barriers for QMS providers, accelerates go-to-market strategy, and strengthens regulatory alignment and localization for regional deployment.
Local Risk & Opportunity Assessment Identification of evolving GxP and data integrity regulations, cybersecurity requirements, validation burdens, and growth opportunities in cloud, AI/ML, and integrated eQMS for pharma and biotech. Supports proactive risk mitigation, regulatory compliance planning, and investment prioritization for next-generation, inspection-ready QMS solutions.
Technology Adoption by Region Mapping of QMS adoption maturity across North America, Europe, and Asia Pacific; analysis of cloud transition trends, integration with MES/LIMS/ERP, and drivers like digital quality initiatives and regulatory harmonization. Guides regional product strategy, R&D focus, and investment in scalable, interoperable QMS solutions aligned with pharma digital transformation and compliance evolution.

RECENT DEVELOPMENTS

  • August 2025 : Veeva Systems and IQVIA partnered to deliver integrated clinical and commercial solutions, including quality management, enabling life sciences customers to leverage combined capabilities.
  • March 2025 : MasterControl Solutions, Inc. acquired Qualer to integrate asset tracking, calibration, and maintenance functionalities into its existing quality and manufacturing software platform.
  • October 2024 : Honeywell expanded its partnership with Salesforce to integrate TrackWise Quality and Life Sciences Cloud, offering unified digital solutions that streamline pharma and medtech quality, compliance, and collaboration.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
28
2
EXECUTIVE SUMMARY
 
 
 
 
 
33
3
PREMIUM INSIGHTS
 
 
 
 
 
38
4
MARKET OVERVIEW
Global pharma's push for efficiency drives demand for AI-enhanced quality management amidst regulatory challenges.
 
 
 
 
 
42
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
STRINGENT REGULATORY COMPLIANCE
 
 
 
 
 
 
4.2.1.2
GLOBALIZATION OF PHARMACEUTICAL OPERATIONS
 
 
 
 
 
 
4.2.1.3
GROWING DEMAND FOR OPERATIONAL EFFICIENCY AND REDUCE HUMAN ERRORS
 
 
 
 
 
 
4.2.1.4
INCREASING EMPHASIS ON RISK MANAGEMENT AND ADHERENCE TO REGULATORY STANDARDS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
RELUCTANCE TO ADOPT NEW SOFTWARE SOLUTIONS
 
 
 
 
 
 
4.2.2.2
STRICT DATA PROTECTION LAWS
 
 
 
 
 
 
4.2.2.3
DATA SECURITY AND PRIVACY CONCERNS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
INCREASING DEMAND FOR SPECIALIZED CLOUD-BASED SOFTWARE SOLUTIONS
 
 
 
 
 
 
4.2.3.2
RISING NUMBER OF SMALL & MID-SIZED PHARMA COMPANIES
 
 
 
 
 
 
4.2.3.3
EXPANDING PHARMACEUTICAL INDUSTRY IN EMERGING REGIONS
 
 
 
 
 
 
4.2.3.4
ADOPTION OF AI AND ADVANCED ANALYTICS
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
HIGH INITIAL COSTS OF IMPLEMENTING QUALITY MANAGEMENT SYSTEMS
 
 
 
 
 
 
4.2.4.2
VARIABILITY IN REGULATORY STANDARDS
 
 
 
 
 
 
4.2.4.3
SHORTAGE OF SKILLED R&D AND QUALITY PROFESSIONALS
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate industry shifts with strategic insights from comprehensive market forces and pricing analyses.
 
 
 
 
 
53
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.2
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
 
 
 
 
 
 
5.5.2
INDICATIVE PRICING ANALYSIS, BY REGION, 2024
 
 
 
 
 
5.6
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
 
 
 
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.10
IMPACT OF 2025 US TARIFF
 
 
 
 
 
 
 
 
5.10.1
INTRODUCTION
 
 
 
 
 
 
5.10.2
KEY TARIFF RATES
 
 
 
 
 
 
5.10.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.10.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.10.4.1
US
 
 
 
 
 
 
5.10.4.2
EUROPE
 
 
 
 
 
 
5.10.4.3
ASIA PACIFIC
 
 
 
 
 
5.10.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.10.5.1
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
5.10.5.2
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.10.5.3
CONTRACT RESEARCH ORGANIZATIONS (CROS)
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations redefine pharmaceutical quality management, enhancing compliance and optimizing interconnected ecosystems.
 
 
 
 
 
70
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
GENERATIVE AI & MACHINE LEARNING
 
 
 
 
 
 
6.1.2
CLOUD COMPUTING & SAAS PLATFORMS
 
 
 
 
 
 
6.1.3
ROBOTIC PROCESS AUTOMATION
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
MANUFACTURING EXECUTION SYSTEMS (MES)
 
 
 
 
 
 
6.2.2
ENTERPRISE RESOURCE PLANNING (ERP) SYSTEMS
 
 
 
 
 
 
6.2.3
ELECTRONIC DATA MANAGEMENT SYSTEMS (EDMS)
 
 
 
 
 
6.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.4
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.4.1
JURISDICTION ANALYSIS
 
 
 
 
 
 
6.4.2
MAJOR PATENTS
 
 
 
 
 
 
6.4.3
LIST OF PATENTS
 
 
 
 
 
6.5
FUTURE APPLICATIONS
 
 
 
 
 
 
 
6.5.1
AUTOMATED AUDIT AND INSPECTION
 
 
 
 
 
 
6.5.2
AI-POWERED COMPLIANCE MONITORING
 
 
 
 
 
 
6.5.3
ADVANCED ANALYTICS DASHBOARDS
 
 
 
 
 
 
6.5.4
MOBILE QMS APPLICATIONS
 
 
 
 
 
 
6.5.5
SUPPLIER QUALITY MANAGEMENT AUTOMATION
 
 
 
 
 
6.6
IMPACT OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET
 
 
 
 
 
 
 
 
6.6.1
INTRODUCTION
 
 
 
 
 
 
6.6.2
MARKET POTENTIAL OF AI/GEN AI IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET
 
 
 
 
 
 
6.6.3
CASE STUDY RELATED TO AI/GEN AI IMPLEMENTATION
 
 
 
 
 
 
 
6.6.3.1
USE OF UNIFIED QMS PLATFORM FOR QUALITY DOCUMENTATION
 
 
 
 
 
6.6.4
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 
 
 
 
 
 
 
6.6.4.1
AUTOMATED AUDIT SIMULATION
 
 
 
 
 
 
6.6.4.2
REAL-TIME MONITORING & ALERTS
 
 
 
 
 
 
6.6.4.3
REGULATORY & COMPLIANCE SERVICES
 
 
 
 
 
 
6.6.4.4
RESEARCH LABORATORIES & CONTRACT MANUFACTURERS
 
 
 
 
 
6.6.5
USER READINESS AND IMPACT ASSESSMENT
 
 
 
 
 
 
 
6.6.5.1
USER READINESS
 
 
 
 
 
 
 
 
6.6.5.1.1
USER A: PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
6.6.5.1.2
USER B: BIOTECHNOLOGY COMPANIES
 
 
 
 
6.6.5.2
IMPACT ASSESSMENT
 
 
 
 
 
 
 
 
6.6.5.2.1
USER A: PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
6.6.5.2.2
USER B: BIOTECHNOLOGY COMPANIES
 
7
REGULATORY LANDSCAPE
Navigate complex global regulations with region-specific insights and compliance strategies.
 
 
 
 
 
84
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
 
 
7.1.2.1
NORTH AMERICA
 
 
 
 
 
 
7.1.2.2
EUROPE
 
 
 
 
 
 
7.1.2.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.2.4
MIDDLE EAST & AFRICA
 
 
 
 
 
 
7.1.2.5
LATIN AMERICA
 
 
 
8
CUSTOMER LANDSCAPE & BUYING BEHAVIOUR
Unlocking stakeholder influence and unmet needs to refine buying strategies in diverse industries.
 
 
 
 
 
91
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYERS STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA
 
 
 
 
 
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
9
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 9 Data Tables
 
 
 
 
 
94
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
CLINICAL TRIALS
 
 
 
 
 
 
 
9.2.1
NEED TO ENSURE CLINICAL EXCELLENCE AND REGULATORY INTEGRITY TO EXPEDITE GROWTH
 
 
 
 
 
9.3
REGULATORY COMPLIANCE
 
 
 
 
 
 
 
9.3.1
INCREASING EMPHASIS ON COMPLYING WITH STRINGENT INTERNATIONAL STANDARDS TO AID GROWTH
 
 
 
 
 
9.4
MANUFACTURING/PRODUCTION
 
 
 
 
 
 
 
9.4.1
GROWING FOCUS ON CONSISTENT PRODUCT QUALITY TO DRIVE MARKET
 
 
 
 
 
9.5
QUALITY ASSURANCE/QUALITY CONTROL
 
 
 
 
 
 
 
9.5.1
INCREASING FOCUS ON CONTINUOUS MONITORING, DOCUMENTATION, AND CONTROL IN PHARMA PRODUCTION TO FAVOR GROWTH
 
 
 
 
 
9.6
DISTRIBUTION & SUPPLY CHAIN
 
 
 
 
 
 
 
9.6.1
COMPLEX GLOBAL SUPPLY NETWORKS TO CONTRIBUTE TO GROWTH
 
 
 
 
 
9.7
COMMERCIALIZATION, MARKETING, AND SALES
 
 
 
 
 
 
 
9.7.1
RISING INTRODUCTION OF COMPLEX THERAPIES AND EVOLVING REGULATIONS TO SUSTAIN GROWTH
 
 
 
 
 
9.8
POST-MARKET SURVEILLANCE
 
 
 
 
 
 
 
9.8.1
GROWING FOCUS ON PRODUCT PERFORMANCE AND PATIENT SAFETY TO BOOST MARKET
 
 
 
 
 
9.9
OTHER PROCESSES
 
 
 
 
 
10
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 10 Data Tables
 
 
 
 
 
104
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
DOCUMENT CONTROL & ESOP
 
 
 
 
 
 
 
10.2.1
NEED TO MANAGE AND CONTROL CRITICAL QUALITY DOCUMENTS TO FACILITATE GROWTH
 
 
 
 
 
10.3
CAPA (CORRECTIVE AND PREVENTIVE ACTION) MANAGEMENT
 
 
 
 
 
 
 
10.3.1
ABILITY TO ADDRESS DETECTION, RESOLUTION, AND PREVENTION OF QUALITY AND COMPLIANCE ISSUES TO FUEL MARKET
 
 
 
 
 
10.4
AUDIT & INSPECTION MANAGEMENT
 
 
 
 
 
 
 
10.4.1
INCREASING FOCUS ON EFFECTIVE AUDIT AND INSPECTION MANAGEMENT TO BOLSTER GROWTH
 
 
 
 
 
10.5
TRAINING MANAGEMENT
 
 
 
 
 
 
 
10.5.1
RISING AUTOMATION AND STANDARDIZATION IN TRAINING ACTIVITIES TO ADVANCE GROWTH
 
 
 
 
 
10.6
REGULATORY & COMPLIANCE MANAGEMENT
 
 
 
 
 
 
 
10.6.1
EVOLVING GLOBAL REGULATORY REQUIREMENTS TO ACCELERATE GROWTH
 
 
 
 
 
10.7
SUPPLIER QUALITY MANAGEMENT
 
 
 
 
 
 
 
10.7.1
NEED TO MAINTAIN SUPPLIER RELIABILITY, MATERIAL INTEGRITY, AND REGULATORY COMPLIANCE TO SPUR GROWTH
 
 
 
 
 
10.8
RISK MANAGEMENT
 
 
 
 
 
 
 
10.8.1
COMPLEX NATURE OF PHARMACEUTICAL OPERATIONS TO ENCOURAGE GROWTH
 
 
 
 
 
10.9
CHANGE CONTROL MANAGEMENT
 
 
 
 
 
 
 
10.9.1
RISING TRANSITION TOWARD DIGITAL SYSTEMS TO STIMULATE GROWTH
 
 
 
 
 
10.10
OTHER APPLICATIONS
 
 
 
 
 
11
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 3 Data Tables
 
 
 
 
 
115
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
LARGE ENTERPRISES
 
 
 
 
 
 
 
11.2.1
RISING DIGITAL TRANSFORMATION AND COMPLIANCE MODERNIZATION STRATEGIES TO EXPEDITE GROWTH
 
 
 
 
 
11.3
SMALL & MEDIUM ENTERPRISES
 
 
 
 
 
 
 
11.3.1
INCREASING ADOPTION OF CLOUD-BASED, MODULAR, AND SCALABLE QMS SOLUTIONS TO AID GROWTH
 
 
 
 
12
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 6 Data Tables
 
 
 
 
 
119
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
 
12.2.1
INCREASING INVESTMENTS IN AI AND ANALYTICS-ENABLED QMS PLATFORMS TO PROPEL MARKET
 
 
 
 
 
12.3
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
12.3.1
STRONG FOCUS ON INNOVATION, REGULATORY COMPLIANCE, AND MANUFACTURING PRECISION TO FAVOR GROWTH
 
 
 
 
 
12.4
CONTRACT RESEARCH ORGANIZATIONS
 
 
 
 
 
 
 
12.4.1
INCREASING CLINICAL RESEARCH, DATA MANAGEMENT, AND REGULATORY SUBMISSION ACTIVITIES TO SUSTAIN GROWTH
 
 
 
 
 
12.5
CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
 
 
 
 
 
 
 
12.5.1
CRUCIAL ROLE IN GLOBAL DRUG PRODUCTION, FORMULATION DEVELOPMENT, AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET
 
 
 
 
 
12.6
OTHER END USERS
 
 
 
 
 
13
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 17 Countries | 120 Data Tables.
 
 
 
 
 
126
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
NORTH AMERICA
 
 
 
 
 
 
 
13.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
13.2.2
US
 
 
 
 
 
 
 
13.2.2.1
GROWING NEED FOR OPERATIONAL EXCELLENCE IN LIFE SCIENCES SECTOR TO BOOST MARKET
 
 
 
 
 
13.2.3
CANADA
 
 
 
 
 
 
 
13.2.3.1
INCREASING DIGITAL TRANSFORMATION INITIATIVES AND FOCUS ON LIFECYCLE QUALITY MANAGEMENT TO AID GROWTH
 
 
 
 
13.3
EUROPE
 
 
 
 
 
 
 
13.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
13.3.2
GERMANY
 
 
 
 
 
 
 
13.3.2.1
ROBUST PHARMA INFRASTRUCTURE TO PROPEL MARKET
 
 
 
 
 
13.3.3
UK
 
 
 
 
 
 
 
13.3.3.1
INCREASING FOCUS ON COMPREHENSIVE PATIENT SAFETY AND RISK MANAGEMENT SOLUTIONS TO SPUR GROWTH
 
 
 
 
 
13.3.4
FRANCE
 
 
 
 
 
 
 
13.3.4.1
STRICT REGULATORY ENVIRONMENT TO FOSTER GROWTH
 
 
 
 
 
13.3.5
ITALY
 
 
 
 
 
 
 
13.3.5.1
RISING COMPLIANCE MANDATES TO CONTRIBUTE TO GROWTH
 
 
 
 
 
13.3.6
SPAIN
 
 
 
 
 
 
 
13.3.6.1
NEED FOR SCALABLE, COST-EFFECTIVE, AND REGULATORY-READY SYSTEMS TO AUGMENT GROWTH
 
 
 
 
 
13.3.7
REST OF EUROPE
 
 
 
 
 
13.4
ASIA PACIFIC
 
 
 
 
 
 
 
13.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
13.4.2
CHINA
 
 
 
 
 
 
 
13.4.2.1
RISING CLINICAL & MANUFACTURING VOLUMES AND GROWING NUMBER OF BIOTECH COMPANIES TO DRIVE MARKET
 
 
 
 
 
13.4.3
JAPAN
 
 
 
 
 
 
 
13.4.3.1
INCREASING ADOPTION OF CLOUD SYSTEMS AND ELECTRONIC RECORDS TO AID GROWTH
 
 
 
 
 
13.4.4
INDIA
 
 
 
 
 
 
 
13.4.4.1
EXPANDING PHARMACEUTICAL MANUFACTURING BASE AND INCREASING REGULATORY SCRUTINY FROM GLOBAL HEALTH AUTHORITIES TO DRIVE MARKET
 
 
 
 
 
13.4.5
AUSTRALIA
 
 
 
 
 
 
 
13.4.5.1
INCREASING SHIFT TOWARD ELECTRONIC INTEGRATED QUALITY ECOSYSTEMS TO PROMOTE GROWTH
 
 
 
 
 
13.4.6
SOUTH KOREA
 
 
 
 
 
 
 
13.4.6.1
GROWING FOCUS ON LIFECYCLE QUALITY MANAGEMENT TO PROPEL MARKET
 
 
 
 
 
13.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
13.5
LATIN AMERICA
 
 
 
 
 
 
 
13.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
13.5.2
BRAZIL
 
 
 
 
 
 
 
13.5.2.1
GROWING INVESTMENTS IN AUTOMATED QUALITY SYSTEMS TO DRIVE MARKET
 
 
 
 
 
13.5.3
MEXICO
 
 
 
 
 
 
 
13.5.3.1
INCREASING EMPHASIS ON DATA INTEGRITY AND ELECTRONIC DOCUMENTATION TO BOOST MARKET
 
 
 
 
 
13.5.4
REST OF LATIN AMERICA
 
 
 
 
 
13.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
13.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
13.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
13.6.2.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
13.6.2.1.1
INCREASING LOCAL MANUFACTURING AND ENHANCED REGULATORY COMPLIANCE TO PROMOTE GROWTH
 
 
 
 
13.6.2.2
UAE
 
 
 
 
 
 
 
 
13.6.2.2.1
RISING REGULATORY MODERNIZATION AND NATIONAL MANUFACTURING INITIATIVES TO SUSTAIN GROWTH
 
 
 
 
13.6.2.3
REST OF GCC COUNTRIES
 
 
 
 
 
13.6.3
SOUTH AFRICA
 
 
 
 
 
 
 
13.6.3.1
EVOLVING REGULATORY EXPECTATIONS AND DIGITALIZATION TRENDS TO FUEL MARKET
 
 
 
 
 
13.6.4
REST OF MIDDLE EAST & AFRICA
 
 
 
 
14
COMPETITIVE LANDSCAPE
Analyze key players' strategies and market share dominance in the evolving competitive landscape.
 
 
 
 
 
202
 
14.1
OVERVIEW
 
 
 
 
 
 
14.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
 
 
 
 
 
14.3
REVENUE SHARE ANALYSIS
 
 
 
 
 
 
14.4
MARKET SHARE ANALYSIS
 
 
 
 
 
 
 
14.5
SOFTWARE COMPARISON
 
 
 
 
 
 
14.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
 
 
14.6.1
STARS
 
 
 
 
 
 
14.6.2
EMERGING LEADERS
 
 
 
 
 
 
14.6.3
PERVASIVE PLAYERS
 
 
 
 
 
 
14.6.4
PARTICIPANTS
 
 
 
 
 
 
14.6.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
 
 
14.6.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
14.6.5.2
REGION FOOTPRINT
 
 
 
 
 
 
14.6.5.3
PROCESS FOOTPRINT
 
 
 
 
 
 
14.6.5.4
APPLICATION FOOTPRINT
 
 
 
 
 
 
14.6.5.5
ENTERPRISE SIZE FOOTPRINT
 
 
 
 
 
 
14.6.5.6
END-USER FOOTPRINT
 
 
 
 
14.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
 
14.7.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
14.7.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
14.7.3
DYNAMIC COMPANIES
 
 
 
 
 
 
14.7.4
STARTING BLOCKS
 
 
 
 
 
 
14.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
14.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
14.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
14.8
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
 
14.8.1
COMPANY VALUATION
 
 
 
 
 
 
14.8.2
FINANCIAL METRICS
 
 
 
 
 
14.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
14.9.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
14.9.2
DEALS
 
 
 
 
 
 
14.9.3
EXPANSIONS
 
 
 
 
 
 
14.9.4
OTHER DEVELOPMENTS
 
 
 
 
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
225
 
15.1
KEY PLAYERS
 
 
 
 
 
 
 
15.1.1
HONEYWELL INTERNATIONAL INC.
 
 
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
15.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
15.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
15.1.1.3.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
15.1.1.3.2
DEALS
 
 
 
 
15.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
15.1.1.4.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
 
15.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
15.1.1.4.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.2
IQVIA
 
 
 
 
 
 
15.1.3
VEEVA SYSTEMS INC.
 
 
 
 
 
 
15.1.4
MASTERCONTROL SOLUTIONS, INC.
 
 
 
 
 
 
15.1.5
DASSAULT SYSTÈMES
 
 
 
 
 
 
15.1.6
QUALIO
 
 
 
 
 
 
15.1.7
HEXAGON AB
 
 
 
 
 
 
15.1.8
ASSURX, INC.
 
 
 
 
 
 
15.1.9
QT9 SOFTWARE
 
 
 
 
 
 
15.1.10
COMPLIANCEQUEST
 
 
 
 
 
 
15.1.11
IDEAGEN
 
 
 
 
 
 
15.1.12
SOFTEXPERT
 
 
 
 
 
 
15.1.13
INSTEM
 
 
 
 
 
 
15.1.14
INTELEX TECHNOLOGIES
 
 
 
 
 
 
15.1.15
INTELLECT, INC
 
 
 
 
 
 
15.1.16
AMPLELOGIC
 
 
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
 
 
15.2.1
INSTANTGMP
 
 
 
 
 
 
15.2.2
SIMPLERQMS
 
 
 
 
 
 
15.2.3
DOT COMPLIANCE LTD.
 
 
 
 
 
 
15.2.4
SNIC SOLUTIONS
 
 
 
 
 
 
15.2.5
QUALITYZE
 
 
 
 
 
 
15.2.6
SCIGENIQ
 
 
 
 
 
 
15.2.7
KIVO, INC.
 
 
 
 
 
 
15.2.8
GMP SOFTWARE INDIA PVT. LTD.
 
 
 
 
 
 
15.2.9
VMT SOFT SOL PVT. LTD.
 
 
 
 
16
RESEARCH METHODOLOGY
 
 
 
 
 
278
 
16.1
RESEARCH DATA
 
 
 
 
 
 
 
16.1.1
SECONDARY DATA
 
 
 
 
 
 
 
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
16.1.2
PRIMARY DATA
 
 
 
 
 
 
 
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
16.1.2.2
KEY PRIMARY PARTICIPANTS
 
 
 
 
 
 
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
16.1.2.4
KEY INDUSTRY INSIGHTS
 
 
 
 
16.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
16.3
DATA TRIANGULATION
 
 
 
 
 
 
16.4
FACTOR ANALYSIS
 
 
 
 
 
 
16.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
 
16.5.1
MARKET SIZING ASSUMPTIONS
 
 
 
 
 
 
16.5.2
STUDY ASSUMPTIONS
 
 
 
 
 
16.6
RESEARCH LIMITATIONS AND RISK ASSESSMENT
 
 
 
 
 
 
 
16.6.1
RESEARCH LIMITATIONS
 
 
 
 
 
 
 
16.6.1.1
METHODOLOGY-RELATED LIMITATIONS
 
 
 
 
 
 
16.6.1.2
SCOPE-RELATED LIMITATIONS
 
 
 
 
 
16.6.2
RISK ASSESSMENT
 
 
 
 
17
APPENDIX
 
 
 
 
 
294
 
17.1
DISCUSSION GUIDE
 
 
 
 
 
 
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
17.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE: INCLUSIONS AND EXCLUSIONS
 
 
 
 
 
 
TABLE 2
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2025
 
 
 
 
 
 
TABLE 3
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
 
 
 
 
 
 
TABLE 4
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 5
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 6
INDICATIVE PRICING ANALYSIS FOR PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE, BY KEY PLAYER, 2024 (USD)
 
 
 
 
 
 
TABLE 7
INDICATIVE PRICING ANALYSIS FOR PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE, BY PRICING PLANS, 2024 (USD)
 
 
 
 
 
 
TABLE 8
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
TABLE 9
CASE STUDY 1: IMPROVED COMPLIANCE & EFFICIENCY WITH CONFIGURABLE EQMS
 
 
 
 
 
 
TABLE 10
CASE STUDY 2: STREAMLINED CHANGE CONTROL & DOCUMENT MANAGEMENT WITH TRACKWISE DIGITAL
 
 
 
 
 
 
TABLE 11
US ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 12
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, JANUARY 2015–NOVEMBER 2025
 
 
 
 
 
 
TABLE 13
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
 
 
 
 
 
 
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 17
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
REGULATORY SCENARIO OF NORTH AMERICA
 
 
 
 
 
 
TABLE 20
REGULATORY SCENARIO OF EUROPE
 
 
 
 
 
 
TABLE 21
REGULATORY SCENARIO OF ASIA PACIFIC
 
 
 
 
 
 
TABLE 22
REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 23
REGULATORY SCENARIO OF LATIN AMERICA
 
 
 
 
 
 
TABLE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
 
 
 
 
 
 
TABLE 25
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
TABLE 26
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: UNMET NEEDS
 
 
 
 
 
 
TABLE 27
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 28
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CLINICAL TRIALS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 29
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 30
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR MANUFACTURING/PRODUCTION, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 31
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR QUALITY ASSURANCE/QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 32
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR DISTRIBUTION & SUPPLY CHAIN, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 33
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR COMMERCIALIZATION, MARKETING, AND SALES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 34
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR POST-MARKET SURVEILLANCE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 35
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER PROCESSES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 36
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 37
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR DOCUMENT & ESOP, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 38
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CAPA (CORRECTIVE & PREVENTIVE ACTION) MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 39
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR AUDIT & INSPECTION MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 40
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR TRAINING MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 41
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR REGULATORY & COMPLIANCE MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 42
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR SUPPLIER QUALITY MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 43
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR RISK MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 44
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CHANGE CONTROL MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 45
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 46
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 47
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR LARGE ENTERPRISES, REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 48
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR SMALL & MEDIUM ENTERPRISES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 49
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 50
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 51
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 52
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 53
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 54
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 55
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 56
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 57
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 58
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 59
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 60
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 61
US: MAJOR COMPANIES IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET
 
 
 
 
 
 
TABLE 62
US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 63
US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 64
US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 65
US: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 66
CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 67
CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 68
CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 69
CANADA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 70
EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 71
EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 72
EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 73
EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 74
EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 75
GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 76
GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 77
GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 78
GERMANY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 79
UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 80
UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 81
UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 82
UK: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 83
FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 84
FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 85
FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 86
FRANCE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 87
ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 88
ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 89
ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 90
ITALY: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 91
SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 92
SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 93
SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 94
SPAIN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 95
REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 96
REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 97
REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 98
REST OF EUROPE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 99
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 101
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 102
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 104
CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 105
CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 106
CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 107
CHINA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 108
JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 109
JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 110
JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 111
JAPAN: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 112
INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 113
INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 114
INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION)
 
 
 
 
 
 
TABLE 115
INDIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 116
AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 117
AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 118
AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 119
AUSTRALIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 120
SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 121
SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 122
SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 123
SOUTH KOREA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 124
REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 125
REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 126
REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 127
REST OF ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 128
LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 129
LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 130
LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 131
LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 132
LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 133
BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 134
BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 135
BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 136
BRAZIL: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 137
MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 138
MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 139
MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION)
 
 
 
 
 
 
TABLE 140
MEXICO: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 141
REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 142
REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030(USD MILLION)
 
 
 
 
 
 
TABLE 143
REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION)
 
 
 
 
 
 
TABLE 144
REST OF LATIN AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 145
MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 146
MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 147
MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 148
MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 149
MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 150
GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 151
GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 152
GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 153
GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 154
GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 155
SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 156
SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 157
SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 158
SAUDI ARABIA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 159
UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 160
UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 161
UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 162
UAE: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 163
REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 164
REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 165
REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030(USD MILLION)
 
 
 
 
 
 
TABLE 166
REST OF GCC COUNTRIES: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 167
SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 168
SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 169
SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 170
SOUTH AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 171
REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 172
REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 173
REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 174
REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
 
 
TABLE 175
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 176
PHARMACEUTICAL QUALITY MANAGEMENT MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 177
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 178
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PROCESS FOOTPRINT
 
 
 
 
 
 
TABLE 179
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 180
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: ENTERPRISE SIZE FOOTPRINT
 
 
 
 
 
 
TABLE 181
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: END-USER FOOTPRINT
 
 
 
 
 
 
TABLE 182
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 183
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 184
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 185
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 186
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 187
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 188
HONEYWELL INTERNATIONAL INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 189
HONEYWELL INTERNATIONAL INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 190
HONEYWELL INTERNATIONAL INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 191
HONEYWELL INTERNATIONAL INC.: JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 192
IQVIA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 193
IQVIA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 194
IQVIA: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 195
IQVIA: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 196
VEEVA SYSTEMS INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 197
VEEVA SYSTEMS INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 198
VEEVA SYSTEMS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 199
VEEVA SYSTEMS INC.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 200
MASTERCONTROL SOLUTIONS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 201
MASTERCONTROL SOLUTIONS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 202
MASTERCONTROL SOLUTIONS, INC.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 203
DASSAULT SYSTÈMES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 204
DASSAULT SYSTÈMES: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 205
QUALIO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 206
QUALIO: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 207
HEXAGON AB: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 208
HEXAGON AB: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 209
HEXAGON AB: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 210
HEXAGON AB.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 211
ASSURX, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 212
ASSURX, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 213
ASSURX, INC.: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 214
QT9 SOFTWARE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 215
QT9 SOFTWARE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 216
QT9 SOFTWARE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 217
QT9 SOFTWARE: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 218
COMPLIANCEQUEST: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 219
COMPLIANCEQUEST: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 220
COMPLIANCEQUEST: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 221
IDEAGEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 222
IDEAGEN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 223
IDEAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 224
IDEAGEN: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 225
SOFTEXPERT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 226
SOFTEXPERT: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 227
SOFTEXPERT: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 228
INSTEM: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 229
INSTEM: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 230
INSTEM: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 231
INTELEX TECHNOLOGIES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 232
INTELEX TECHNOLOGIES: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 233
INTELEX TECHNOLOGIES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– OCTOBER 2025
 
 
 
 
 
 
TABLE 234
INTELEX TECHNOLOGIES: EXPANSIONS, JANUARY 2022–OCTOBER 2024
 
 
 
 
 
 
TABLE 235
INTELLECT, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 236
INTELLECT, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 237
INTELLECT, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 238
AMPLELOGIC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 239
AMPLELOGIC: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 240
AMPLELOGIC: DEALS, JANUARY 2022–OCTOBER 2025
 
 
 
 
 
 
TABLE 241
INSTANTGMP: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 242
SIMPLERQMS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 243
DOT COMPLIANCE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 244
SNIC SOLUTIONS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 245
QUALITYZE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 246
SCIGENIQ: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 247
KIVO, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 248
GMP SOFTWARE INDIA PVT. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 249
VMT SOFT SOL PVT. LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 250
FACTOR ANALYSIS
 
 
 
 
 
 
TABLE 251
MARKET SIZING ASSUMPTIONS
 
 
 
 
 
 
TABLE 252
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SEGMENTATION AND REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 3
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030
 
 
 
 
 
 
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2023–2030
 
 
 
 
 
 
FIGURE 5
DISRUPTIONS INFLUENCING GROWTH OF PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET
 
 
 
 
 
 
FIGURE 6
HIGH-GROWTH SEGMENTS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET, 2025–2030
 
 
 
 
 
 
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
INCREASING ENFORCEMENT OF GLOBAL QUALITY STANDARDS AND REGULATORY UPGRADES TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 9
LARGE ENTERPRISES AND US LED NORTH AMERICAN MARKET IN 2024
 
 
 
 
 
 
FIGURE 10
CANADA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
EMERGING MARKETS TO HAVE HIGHER GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 13
US MEDIAN HEALTHCARE DATA BREACH, 2009–2024
 
 
 
 
 
 
FIGURE 14
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 15
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 16
NEW REVENUE POCKETS AND REVENUE SHIFT IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET
 
 
 
 
 
 
FIGURE 17
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
FIGURE 18
JURISDICTION ANALYSIS, JANUARY 2015–NOVEMBER 2025
 
 
 
 
 
 
FIGURE 19
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: PATENT ANALYSIS, JANUARY 2015–NOVEMBER 2024
 
 
 
 
 
 
FIGURE 20
MARKET POTENTIAL OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET ACROSS INDUSTRIES
 
 
 
 
 
 
FIGURE 21
IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 
 
 
 
 
 
FIGURE 22
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
 
 
 
 
 
 
FIGURE 23
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 24
NORTH AMERICA: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 25
ASIA PACIFIC: PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 (USD MILLION)
 
 
 
 
 
 
FIGURE 27
MARKET SHARE ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, 2024
 
 
 
 
 
 
FIGURE 28
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: SOFTWARE COMPARISON
 
 
 
 
 
 
FIGURE 29
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 30
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 31
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 33
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 34
HONEYWELL INTERNATIONAL INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 35
IQVIA: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 36
VEEVA SYSTEMS INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 37
DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 38
HEXAGON AB: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 39
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 40
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 41
SUPPLY-SIDE MARKET ESTIMATION
 
 
 
 
 
 
FIGURE 42
PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: REVENUE ESTIMATION APPROACH
 
 
 
 
 
 
FIGURE 43
BOTTOM-UP APPROACH: END-USER SPENDING ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE
 
 
 
 
 
 
FIGURE 44
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 45
DATA TRIANGULATION
 
 
 
 
 
 
FIGURE 46
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2025–2030
 
 
 
 
 
 
FIGURE 47
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 

Methodology

The study involved several key activities to estimate the current size of the pharmaceutical quality management software (QMS) market. Extensive secondary research was conducted to gather information on this market. The next step was to validate the findings, assumptions, and size estimates by consulting industry experts throughout the value chain through primary research. We employed various methods, including top-down and bottom-up approaches, to estimate the overall market size. Following this, we utilized market segmentation and data triangulation techniques to determine the size of specific segments and subsegments within the pharmaceutical quality management softwarecare market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Business, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for companies providing pharmaceutical quality management software care solutions is assessed using secondary data from both paid and free sources. This involves analysing the product portfolios of major players in the industry and evaluating these companies based on their performance and quality. Various resources were utilized in the secondary research process to gather information for this study. The sources include annual reports, press releases, investor presentations, white papers, academic journals, certified publications, articles by recognized authors, directories, and databases.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the pharmaceutical quality management software market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players.

After completing the market engineering process, which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation, extensive primary research was conducted. This research aimed to gather information and verify the critical numbers obtained during the market analysis. Additionally, primary research was conducted to identify different types of market segmentation, analyse industry trends, evaluate the competitive landscape of pharmaceutical quality management software care offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market participants.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Pharmaceutical Quality Management Software Market
 Size, and Share

Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by process, application, enterprise size, end users, and region).

Pharmaceutical Quality Management Software Market: Top-Down and Bottom-Up Approach

Pharmaceutical Quality Management Software Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size, using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the pharmaceutical quality management software market.

Market Definition

Pharmaceutical quality management software is a formalized, electronic system designed to document, automate, and manage all processes, procedures, and responsibilities associated with ensuring the quality and regulatory compliance of pharmaceutical products throughout their lifecycle. It serves as a centralized platform for managing critical quality activities including document control, SOPs, CAPA, audits, training, risk management, and supplier quality to ensure product safety, efficacy, and regulatory compliance..

Key Stakeholders

  • Pharmaceutical companies
  • Pharmaceutical quality management software Providers
  • Biotechnology firms
  • Academic Research Institutes
  • Contract Manufacturing Organizations
  • Contract Research Organizations
  • Market Research and Consulting Firms
  • Regulatory Authorities / Agencies
  • Quality Assurance & Quality Control Departments
  • Research & Development (R&D) Teams
  • Third-party Auditors / Inspections Bodies
  • Suppliers / Raw Material Vendors

Report Objectives

  • To define, describe, and forecast the global pharmaceutical quality management software market based on process, application, enterprise size, end users, and region.
  • To provide detailed information regarding the factors influencing the growth of the market (such as the drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical quality management software market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the pharmaceutical quality management software market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
  • To track and analyze competitive developments such as product & service launches; expansions; partnerships, agreements, and collaborations; and acquisitions in the pharmaceutical quality management software market
  • To benchmark players within the pharmaceutical quality management software market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe Pharmaceutical quality management software Market into Denmark, Norway, and others
  • Further breakdown of the Rest of Asia Pacific Pharmaceutical quality management software Market into Vietnam, Pakistan, New Zealand, and others
  • Further breakdown of the Rest of Latin America Pharmaceutical quality management software Market into Argentina, Chile, Colombia, and others
  • Further breakdown of the Rest of Middle East & Africa Pharmaceutical quality management software Market into Egypt, Nigeria, Israel, and others

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Quality Management Software (QMS) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Pharmaceutical Quality Management Software (QMS) Market

DMCA.com Protection Status